GlassScriptPhysician profile
Caitlyn R Cecil
NPI 1225471782
$3,415.23
in general payments reported to CMS, 2019-2025
28 companies · $619 in 2025
The $619 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $269 · 2021: $272 · 2022: $142 · 2023: $481 · 2024: $583 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $855.11 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $631.00 | 2022-2025 | Azstarys |
| Shire North American Group INC | $371.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.07 | 2019-2025 | Eohilia |
| Sunovion Pharmaceuticals INC. | $227.28 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $220.48 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $200.04 | 2019-2023 | Rexulti, Abilify Maintena |
| Allergan, INC. | $89.05 | 2019-2020 | |
| Genentech USA, INC. | $69.16 | 2019 | |
| Neos Therapeutics, LP | $54.56 | 2019 | |
| Abbvie INC. | $49.48 | 2021 | |
| Tris Pharma INC | $44.79 | 2021-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $42.24 | 2023-2025 | |
| Glaxosmithkline, LLC. | $34.86 | 2019-2024 | Bexsero, Rotarix |
| Kowa Pharmaceuticals America, INC. | $31.65 | 2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.81 | 2022-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $24.95 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $23.86 | 2024 | Ycanth |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.99 | 2025 | |
| Owp Pharmaceuticals, INC. | $18.91 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.43 | 2025 | Gvoke Hypopen |
| Alkermes, INC. | $18.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.07 | 2024 | Flumist Quadrivalent |
| Zyla Life Sciences, INC. | $15.01 | 2019 | |
| Sobi, INC | $13.80 | 2022 | |
| Neurelis, INC. | $13.18 | 2023 | Valtoco |
| Pfizer INC. | $13.10 | 2024 | |
| Biomarin Pharmaceutical INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.